Home > News > 75/Leadless pacemaker implantation: single tertiary centre experience
Devices
Read Time: 2 mins

75/Leadless pacemaker implantation: single tertiary centre experience

Published Online: September 27th 2010 European Journal of Arrhythmia & Electrophysiology. 2020;6(Suppl. 1):abstr75
Authors: S Dalvi (Presenting Author) - Liverpool Heart and Chest Hospital NHS, Liverpool; H Cook - Liverpool Heart and Chest Hospital NHS, Liverpool; A Adlan - Liverpool Heart and Chest Hospital NHS, Liverpool; M Hall - Liverpool Heart and Chest Hospital NHS, Liverpool; A Rao - Liverpool Heart and Chest Hospital NHS, Liverpool
Quick Links:
Article
Article Information
Article:

Background: Leadless pacemakers were developed as an alternative pacing modality in patients who cannot undergo transvenous pacing. Early data suggested a good safety and efficacy profile, however real-world data is limited.

Purpose: To report our single tertiary centre experience in leadless pacemaker implantation.

Methodology: All consecutive patients who underwent leadless pacemaker implantation at Liverpool Heart & Chest Hospital between July 2015 and May 2019 were prospectively included. Written informed consent was obtained from each patient. Femoral venous access was obtained using ultrasound guidance. A 27 Fr delivery sheath was inserted via the femoral vein using ultrasound guidance. The Micra™ VR (Medtronic) pacemaker was implanted into the right ventricular septum using fluoroscopy guidance. All procedures were elective and performed under general anaesthesia with planned overnight admission for observation. Clinical Audit & Effectiveness Group (CAEG) approval was obtained and practice in accordance with National Institute of Health & Care Excellence (NICE) guidelines.

In total 28 cases were performed of which 71% were male, median age 68 years. Commonest pacing indications included complete heart block (61%), sinus node dysfunction (25%) and second-degree atrioventricular block (Mobitz type 2) (7%).

Commonest reasons for using a leadless pacemaker included previous system extractions (43%), vascular access restrictions precluding transvenous pacing (21%) and patient preference due to psychological concerns (18%).

Pacing check at the time of insertion were as follows:

  • Mean threshold 0.56 @ 0.24ms ± 0.23
  • Mean R wave measurement 12.2mv ± 5.2
  • Mean impedance 747 ohms ± 190 (mean ± SD)

Acute procedural success was 100%. Acute complications included superficial groin haematoma (n=4), fever treated with antibiotics (n=1) and urinary retention requiring urethral catheterisation (n=1). All patients were followed up in pacing clinic with normal pacemaker function. There were no major long-term complications. One patient developed pacemaker syndrome and required a traditional transvenous DDD pacemaker. At one month follow up 25% were >90% paced, 50% were paced less than 3% and battery longevity was >3.01V (>8 yrs). Our real-world data suggests that leadless pacemaker implantation is a safe and effective alternative for patients who cannot undergo transvenous pacing.

Article Information:

Further Resources

Share this Article
Related Content In Devices
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72